U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07545486) titled 'Ablative Therapy of Oligometastatic Tumor After Response to Conventional First Line Treatment' on April 10.
Brief Summary: Advancements in systemic antineoplastic therapies have led to improved overall survival rates for many solid tumors. However, metastatic disease remains a significant challenge and remains the leading cause of mortality for these patients. Additionally, there is a high attrition rate after first-line standard treatment across various tumor types, with studies indicating that 20-70% of patients may be unable to undergo second-line therapy, depending on the tumor type.
This highlights an urgent need to enhance o...